Kymab, a monoclonal antibody biopharma company based in Cambridge, has appointed Dr Duncan Casson as chief development officer and Professor Ken Smith (pictured) to its scientific advisory board.

In addition, the firm has also taken on Dr George Vassiliou as a senior clinical fellow, with specialisation in haematological cancer.

Dr Casson has over 25 years’ experience in the development of biologics including antibodies, recombinant proteins and autologous therapies. He was previously chief operating officer of PanGenetics.

Ken Smith is Professor of Medicine at the University of Cambridge and a consultant nephrologist and clinical immunologist. He is also head of the department of medicine at Addenbrooke’s Hospital.

He joins Professor Terrence Rabbitts, Professor Douglas Feron and Dr Michael Owen to increase the breadth of medical experience on Kymab’s scientific advisory board.

George Vassiliou is a Wellcome Trust senior clinical fellow. He is also a consultant haematologist at Addenbrooke’s Hospital in Cambridge where he treats patients with these diseases.